Rice Hall James & Associates LLC Acquires New Shares in Core Laboratories Inc. $CLB

Rice Hall James & Associates LLC acquired a new position in Core Laboratories Inc. (NYSE:CLB) in the 2nd quarter, Holdings Channel reports. The firm acquired 101,648 shares of the oil and gas company’s stock, valued at approximately $1,184,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Core Laboratories by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock valued at $418,000 after purchasing an additional 1,170 shares during the last quarter. American Century Companies Inc. increased its position in shares of Core Laboratories by 14.3% during the 2nd quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company’s stock worth $1,533,000 after purchasing an additional 16,677 shares during the last quarter. Quantbot Technologies LP raised its holdings in Core Laboratories by 343.7% in the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock valued at $202,000 after buying an additional 13,571 shares during the period. Sei Investments Co. acquired a new stake in shares of Core Laboratories during the second quarter valued at about $231,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after acquiring an additional 1,040 shares during the period. Institutional investors and hedge funds own 97.81% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CLB. Wall Street Zen upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings upgraded shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Finally, Johnson Rice raised Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Core Laboratories Stock Performance

NYSE CLB opened at $12.45 on Wednesday. The company has a market cap of $570.98 million, a P/E ratio of 22.22, a P/E/G ratio of 3.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. The stock has a 50-day moving average of $11.57 and a two-hundred day moving average of $14.57. Core Laboratories Inc. has a 1-year low of $9.79 and a 1-year high of $20.36.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $124.61 million for the quarter, compared to analyst estimates of $126.26 million. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. As a group, analysts anticipate that Core Laboratories Inc. will post 0.53 EPS for the current year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Monday, August 10th will be paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, August 10th. Core Laboratories’s dividend payout ratio is presently 7.14%.

Insider Transactions at Core Laboratories

In other Core Laboratories news, CEO Lawrence Bruno bought 5,000 shares of Core Laboratories stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $10.78 per share, for a total transaction of $53,900.00. Following the acquisition, the chief executive officer directly owned 262,438 shares in the company, valued at $2,829,081.64. This represents a 1.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.26% of the stock is currently owned by company insiders.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.